Leading into Budget week in Canberra this week, was a journey in planning, months in advance by member based groups, to advocate for new policy and funding changes in the Australian Health System.
Some paths are taken because of new crises to be addressed in the workforce, others in considering new models of care to treat patients, or simply to get new medications onto the PBS.
Australian Health Journal met with a number of industry heads after the budget on their journeys so far in lobbying for change, their achievements, some of the disappointments and their thoughts on the road ahead, with an election round the corner.
Skip ahead:
00:35 Tegan Carrison, Executive Director Australian Association of Psychologists Inc (AAPi)
03:12 John Bruning, CEO Australasian College of Paramedicine (ACP)
09:09 Paul Sadler, CEO Aged and Community Services Australia (ACSA)
12:06 Karen Booth, President Australian Primary Health Care Association (APNA)
19:45 Jo Armstrong, CEO Cystic Fibrosis Australia
23:25 Elizabeth de Somer, CEO Medicines Australia
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
Strengthening Evidence Through Health Research Where Most People Access Healthcare
In February 2025, the Australian Government committed over $22 million for primary care research, including $5.2m awarded to Professor Michael Kidd, Director of the International Centre for Future Health Systems at UNSW and recently appointed Australia’s Chief Medical Officer, to lead the establishment of one of the largest research collaborations in Australia focused on improving primary care.
The Royal Australian College of GPs says a new national multidisciplinary consortium for primary care research is a positive step forward to improve patient care.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
